Navigation Links
Ardea Biosciences, Inc. Reports Third Quarter 2007 Operating and Financial Results
Date:11/14/2007

Recent Accomplishments Include: - Successful completion of Phase 1 studies of novel HIV NNRTI, RDEA806

- Presentation of Phase 1 data on RDEA806 at key infectious disease

conference - Clearance granted by FDA to commence Phase 1 clinical trials in advanced

cancer patients with lead MEK inhibitor, RDEA119 - Presentation of RDEA119 preclinical data at key oncology conference

CARLSBAD, Calif., Nov. 14 /PRNewswire-FirstCall/ -- Ardea Biosciences, Inc. ("Ardea" or the "Company") (Nasdaq: RDEA), a company focused on the discovery and development of small-molecule therapeutics for the treatment of viral diseases, cancer and inflammatory diseases, today reported financial and operating results for the three months and nine months ended September 30, 2007.

Ardea reported a loss applicable to common stockholders of $7.4 million ($0.72 per basic and diluted share) on revenues of $1.1 million for the third quarter of 2007, compared to a profit of $116,000 ($0.01 per share) for the third quarter of 2006. For the nine months ended September 30, 2007, the Company lost $16.2 million ($1.67 per basic and diluted share) on revenues of $2.8 million, compared to a loss of $131,000 ($0.01 per share) for the corresponding nine-month period in 2006. During 2006, the Company had no revenue. The results for the quarter and nine months ended September 30, 2007 include respective non-cash charges of $421,000 ($0.04 per share) and $784,000 ($0.08 per share) for stock compensation expense. The difference between 2007 and 2006 results reflects Ardea's re-start and rebuilding of operations.

"This past quarter proved to be highly productive," said Ba
'/>"/>

SOURCE Ardea Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
2. Ardea Biosciences Announces Changes to Research Management
3. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
4. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
5. Pressure BioSciences, Inc. Issued First Patent in Canada
6. Pressure BioSciences, Inc. Announces CE Mark Approval and Compliance with the IEC 61010-1 Standard for a Second PCT-based Instrument, the Barocycler NEP2320
7. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
8. Pressure BioSciences, Inc. Provides Corporate Update
9. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
10. QMed, Inc. Reports July Medicare SNP Enrollments
11. Phlo Affiliate Reports Expanded Coverage to Oregon Border
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... (PRWEB) July 28, 2014 The National ... in Muncie IN, is pleased to announce that it ... National Museum of the United States Air Force. , ... year-long process that concluded this spring with an on-site ... Dayton, OH museum. , The National Museum of ...
(Date:7/25/2014)... July 26, 2014 "Ischemic Stroke ... 2014" provides data on the Ischemic Stroke and ... elemental information and data relating to the clinical ... View full global Ischemic Stroke Research Report 2014 ... overview of the trial numbers and their recruitment ...
(Date:7/25/2014)... live in each person,s digestive tract. Scientists believe that ... off harmful infections, but their role in human health ... on the role of these bacteria, a team of ... tracked fluctuations in the bacterial populations of two research ... the July 25 issue of the journal Genome ...
(Date:7/25/2014)... , July 25, 2014 ... the "Global Metabolomics Market 2014-2018" report ... http://photos.prnewswire.com/prnh/20130307/600769 Metabolomics or Metabonomics is ... Metabolomics has become a new experimental technique that ... the environmental sciences. Metabolites are small molecules that ...
Breaking Biology Technology:AMA’s National Model Aviation Museum Granted Full Civilian Museum Certification by the National Museum of the United States Air Force 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 2Ischemic Stroke and Cerebral Stroke Global Clinical Trials Review H2, 2014: MarketResearchReports.Biz 3Monitoring the rise and fall of the microbiome 2Monitoring the rise and fall of the microbiome 3Global Metabolomics Market 2014-2018: Key Vendors are Agilent, Bio-Rad, Bruker, Human Metabolome and Metabolon 2
... Supports Program to Recognize Exemplary Work, BRIDGEWATER, ... of oncology nurses, Ortho Biotech Products, L. P.,today ... Healer,Award for Oncology Nursing, which honors one of ... their unwavering,dedication, compassion and helpfulness. Last year, more ...
... Exclusive Rights to Oncology Biomarkers, FREMONT, ... VRML ), a high-value molecular diagnostics company, ... with Johns Hopkins University,on the development of ... disease,detection, classification and monitoring of prevalent cancers, ...
... Pharmaceuticals,Inc. (NYSE: BRL ) today announced that its ... Merck & Co., Inc.,s Fosamax(R),(Alendronate Sodium) Tablets, 70 mg ... Administration (FDA)., The FDA approved the Company,s application ... associated with the,earliest to expire of the patents listed ...
Cached Biology Technology:Call for Entries - 2008 CURE Extraordinary Healer Award for Oncology Nursing 2Vermillion and Johns Hopkins Sign Collaborative Research and License Agreements to Develop Molecular Diagnostic Tests 2Barr Launches Generic Fosamax(R) Tablets, 70 mg 2Barr Launches Generic Fosamax(R) Tablets, 70 mg 3Barr Launches Generic Fosamax(R) Tablets, 70 mg 4
(Date:7/27/2014)... data from over 18,000 patients, scientists have identified ... in Parkinson,s disease, including six that had not ... Nature Genetics , was partially funded by the ... scientists working in NIH laboratories. , "Unraveling the ... the multiple mechanisms involved in this complex disease, ...
(Date:7/25/2014)... colonial era, 100,000s of people lived on the land ... fire to control the availability of plants they used ... to use fire to maintain desired habitat and natural ... Forest Service,s Pacific Southwest Station, will lead a ... Refuge during the Ecological Society of America,s 99th Annual ...
(Date:7/25/2014)... raging this summer and some of the smoke from those ... image collected by the Moderate Resolution Imaging Spectroradiometer (MODIS) aboard ... smoke has descended over the Great Lakes region of the ... image from July 23, 2014 (first image feature highlighted below) ... off southeastward. In the image, it is over Manitoba ...
Breaking Biology News(10 mins):NIH scientists find 6 new genetic risk factors for Parkinson's 2Fire ecology manipulation by California native cultures 2Fire ecology manipulation by California native cultures 3
... A spoonful of medicine goes down a lot easier if ... helpful for women living with HIV/AIDS and managing their chronic ... Bolton School of Nursing at Case Western Reserve University. ... managing other chronic illnesses," said Allison R. Webel, instructor of ...
... Ill. Land and marine iguanas and giant tortoises ... the Galpagos islands are more likely to harbor antibiotic-resistant ... sites on the islands, researchers report in a ... sites from free-living reptiles harbored Escherichia coli ...
... release is available in Spanish . ... because of their characteristics, produce a certain amount of social ... fact that they are subjected to moral conflicts and ethical ... very necessary from a social perspective, as in the case ...
Cached Biology News:CWRU study finds the love of a dog or cat helps women cope with HIV/AIDS 2Patterns of antibiotic-resistant bacteria found in Galapagos reptiles 2Moral imagination as a key to overcoming work-related stigmas 2
Rat Antibody to Mouse TCR VB8.1,8.2:FITC Recognises the V beta 8.1 and V beta 8.2 determinants of the murine T cell receptor. Specificity: mouse TCR VB8.1 and 8.2...
fli-1...
Vesicle Associated Membrane Protein (VAMP 1/2)...
Anti-Mouse Valpha 2 TCR, Purified (Clone B20.1) (rat IgG2a)...
Biology Products: